Antengene, a China- and US-based cancer drug developer backed by Boyu Capital, has raised about HK$2.8 billion ($361 million) in an initial public offering (IPO) on the Main Board of the Hong Kong stock exchange on Friday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
